<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03835884</url>
  </required_header>
  <id_info>
    <org_study_id>AR-13503-CS201</org_study_id>
    <nct_id>NCT03835884</nct_id>
  </id_info>
  <brief_title>A Study Assessing AR-13503 Implant Alone and in Combination With Aflibercept in Subjects With nAMD or DME</brief_title>
  <official_title>First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) and Subjects With Diabetic Macular Edema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerie Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerie Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in
      Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic
      Macular Edema (DME)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human 24-week study conducted in 2 sequential stages. Stage 1 is a
      multicenter, open label study of the safety and tolerability of a single intravitreal
      administration of AR-13503 SR Implant in escalating doses and Stage 2 is a multicenter,
      single masked, randomized, parallel group study of the safety and preliminary response of
      AR-13503 SR Implant alone and in combination with aflibercept compared with aflibercept
      alone.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 16, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>No masking (stage 1) and participant (Stage 2)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of ocular and non-ocular TEAEs</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of ocular and non-ocular treatment-emergent adverse events (TEAEs), summarized at the subject level by system organ class and preferred term, and also by severity and relatedness to treatment.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>AR-13503 Implant Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AR-13503 Implant Low Dose (10.6 µg) administered as an intravitreal implant into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR-13503 Implant High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AR-13503 Implant High Dose (21.2 µg) administered as an intravitreal implant into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR-13503 Implant High Dose + Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AR-13503 Implant High Dose (21.2 µg) administered as an intravitreal implant plus intravitreal injections of aflibercept into a single eye of up to 18 subjects (9 nAMD and 9 DME) who will be followed for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR-13503 Implant Maximum Dose + Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AR-13503 Implant High Dose (42.4 µg) administered as an intravitreal implant plus intravitreal injections of aflibercept into a single eye of up to 18 subjects (9 nAMD and 9 DME) who will be followed for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR-13503 Implant High Dose + sham</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AR-13503 Implant High Dose (21.2 µg) administered as an intravitreal implant plus sham injections (touch eye only; no injection) into a single eye of up to 18 subjects (9 nAMD and 9 DME)who will be followed for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR-13503 Implant Maximum Dose + sham</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AR-13503 Implant Maximum Dose (42.4 µg) administered as an intravitreal implant plus sham injections (touch eye only; no injection) into a single eye of up to 18 subjects (9 nAMD and 9 DME) who will be followed for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham + Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sham injection (touch eye only; no injection) plus intravitreal injections of Aflibercept into a single eye of up to 18 subjects (9 nAMD and 9 DME) who will be followed for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR-13503 Implant Maximum Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AR-13503 Implant Maximum Dose (42.4 µg) administered as an intravitreal implant into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR-13503 Implant Low Dose</intervention_name>
    <description>AR-13503 Implant Low Dose (10.6 µg) administered as an intravitreal implant into a single eye</description>
    <arm_group_label>AR-13503 Implant Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR-13503 Implant High Dose</intervention_name>
    <description>AR-13503 Implant High Dose (21.2 µg) administered as an intravitreal implant into a single eye</description>
    <arm_group_label>AR-13503 Implant High Dose</arm_group_label>
    <arm_group_label>AR-13503 Implant High Dose + Aflibercept</arm_group_label>
    <arm_group_label>AR-13503 Implant High Dose + sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Intravitreal Injection</description>
    <arm_group_label>AR-13503 Implant High Dose + Aflibercept</arm_group_label>
    <arm_group_label>AR-13503 Implant Maximum Dose + Aflibercept</arm_group_label>
    <arm_group_label>Sham + Aflibercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham injection (Touch eye only; no injection)</description>
    <arm_group_label>AR-13503 Implant High Dose + sham</arm_group_label>
    <arm_group_label>AR-13503 Implant Maximum Dose + sham</arm_group_label>
    <arm_group_label>Sham + Aflibercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR-13503 Implant Maximum Dose</intervention_name>
    <description>AR-13503 Implant Maximum Dose (42.4 µg) administered as an intravitreal implant into a single eye</description>
    <arm_group_label>AR-13503 Implant Maximum Dose</arm_group_label>
    <arm_group_label>AR-13503 Implant Maximum Dose + Aflibercept</arm_group_label>
    <arm_group_label>AR-13503 Implant Maximum Dose + sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Subjects with Neovascular Age-Related Macular Degeneration (nAMD) or
        Diabetic Macular Edema (DME)

          1. 50 years of age or older

          2. Presence of active subfoveal or juxtafoveal Choroidal Neovascularization (CNV) (any
             subtype) with leakage affecting the fovea secondary to Age-Related Macular
             Degeneration (AMD)

          3. Best Corrected Visual Acuity (BCVA) in the study eye at Baseline (Day 0):

             Stage 1: between 65 and 10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters
             (20/50 and 20/640 Snellen equivalent) Stage 2: between 65 and 20 ETDRS letters (20/50
             and 20/400 Snellen equivalent)

          4. Able and willing to give signed informed consent and follow study instructions

        Inclusion Criteria for Subjects with DME

        Subjects with Diabetic Macular Edema (DME) must meet all the following criteria to enter
        into the study:

          1. 18 years of age or older

          2. Type 1 or 2 diabetes mellitus with center-involved DME

          3. BCVA in the study eye at Baseline (Day 0):

             Stage 1: between 65 and 10 ETDRS letters (20/50 and 20/640 Snellen equivalent) Stage
             2: between 65 and 20 ETDRS letters (20/50 and 20/400 Snellen equivalent)

          4. Able and willing to give signed informed consent and follow study instructions

        Exclusion Criteria for Subjects with Neovascular Age-Related Macular Degeneration (nAMD)

        Ophthalmic:

          1. Use of intravitreal aflibercept within 8 weeks, ranibizumab or bevacizumab within 6
             weeks

          2. History of vitreoretinal surgery in the study eye

          3. Any ocular disease in the study eye that in the Investigator and Reading Center's
             opinion may confound assessment of the macula, affect central vision, confound
             results, or preclude improvement in visual acuity

          4. Any current or history of periocular or intraocular inflammation or evidence of
             infection in either eye

          5. Media clarity insufficient to obtain quality fundus and OCT images in the study eye

        Systemic:

          1. History or current systemic condition that in the Investigator opinion preclude the
             safe administration of the study treatment or confound results

          2. History of allergy or sensitivity to fluorescein or povidone iodine

          3. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or
             not using a medically acceptable form of birth control

          4. Participation in an investigational study within 30 days of Screening

        Exclusion Criteria for Subjects with DME

        Ophthalmic:

          1. Use of intraocular or periocular corticosteroids within 6 months, aflibercept within 8
             weeks, ranibizumab or bevacizumab within 6 weeks

          2. History of vitreoretinal surgery in the study eye

          3. High risk proliferative diabetic retinopathy in the study eye and related
             complications

          4. Structural damage to the center or the macula that is likely to preclude improvement
             in visual acuity in the study eye after resolution of the DME

          5. Media clarity insufficient to obtain quality fundus and OCT images in the study eye

        Systemic:

          1. History or current medical condition that in the Investigator's opinion preclude the
             safe administration of the study treatment or confound results

          2. History of allergy or sensitivity to fluorescein or povidone iodine

          3. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or
             not using a medically acceptable form of birth control

          4. Participation in an investigational study within 30 days of Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hayley McKee</last_name>
    <role>Study Director</role>
    <affiliation>Aerie Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Research Institute, LLC</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Retina &amp; Vitreous Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Byers Eye Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doheny Eye Center, UCLA</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants San Diego</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Retina Associates</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Eye Clinic</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Vitreoretinal Associates, P.L.</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, Cole Eye Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina &amp; Vitreous Center of Southern Oregon PM</name>
      <address>
        <city>Ashland</city>
        <state>Oregon</state>
        <zip>97520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Retina, LLP</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Northwest, P.C.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Huntingdon Valley</city>
        <state>Pennsylvania</state>
        <zip>19006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute, P.A.</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Ophthamology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neovascular AMD</keyword>
  <keyword>Diabetic macular edema</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>Vascular endothelial growth factor</keyword>
  <keyword>Intravitreal injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

